David Shalowitz, AB; David Wendler, PhD
Shalowitz D, Wendler D. Informed Consent for Research and Authorization under the Health Insurance Portability and Accountability Act Privacy Rule: An Integrated Approach. Ann Intern Med. 2006;144:685-688. doi: 10.7326/0003-4819-144-9-200605020-00012
Download citation file:
Published: Ann Intern Med. 2006;144(9):685-688.
Researchers have found that implementation of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule is having a negative impact on clinical research. This impact traces, in part, to many research institutions complying with HIPAA by adding lengthy, complex language to their research consent documents. The addition of extensive language burdens institutional review boards and may undermine participants' understanding of the research in which they take part. Comparative analysis reveals, however, that the addition of lengthy text often is unnecessary. The U.S. federal requirements for informed consent for human subjects research and the HIPAA Privacy Rule's requirements for individual authorization overlap substantially. Hence, consent forms that satisfy the U.S. federal regulations for human subjects research need only minimal additional text to also satisfy the authorization requirements under the HIPAA Privacy Rule.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
King K. Holmes
University of Washington
May 2, 2006
Congratulations for this well reasoned contribution.
David A. Gorelick
National Institute on Drug Abuse
May 28, 2006
The HIPAA Privacy Rule and research consent documents
To the Editor: Shalowitz and Wendler (1) provide some helpful suggestions for reducing the length and complexity of research consent documents that also comply with Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule requirements. However, I believe that one of their recommendations is not as straightforward as they present.
Shalowitz and Wendler (1) suggest that research consent documents incorporate the HIPAA requirement that revocation of authorization (i.e., consent to research participation) be in writing. They acknowledge that written revocation of consent is not a requirement of the federal regulations for human research subject protection (45 CFR 46), but do not address how adding a requirement for written withdrawal might influence the voluntariness of continued research participation. One can easily construct scenarios for biomedical research in which only oral communication is possible or practical for at least a certain time interval. For example, the subject might be lying enclosed within a scanning device for several hours. A requirement for written, rather than oral, withdrawal might force subjects to temporarily continue participation after they had decided to withdraw, at least until the procedure was completed and writing was possible again. This seems to contradict the spirit, if not the letter, of 45 CFR 46.
My impression is that current clinical research practice is to promptly honor oral requests from subjects to withdraw from research participation, or to at least suspend further procedures pending a fuller discussion with the subject. A brief review of several IRB web sites found none that required written withdrawal from research participation. Imposing such a requirement is one recommendation that would not enhance human research subject protection.
Reference 1. Shalowitz D & Wendler D. Informed consent for research and authorization under the Health Insurance Portability and Accountability Act privacy rule: An integrated approach. Ann Int Med 2006;144:685-688.
June 29, 2006
We agree with Dr. Gorelick that the right to withdrawal from research participation is a vital safeguard, and investigators should respect research participants' decision to withdrawal, no matter how it is expressed. We did not mean to suggest otherwise. Rather, we recommended that, when applicable, research participants should be informed that the HIPAA Privacy Rule allows investigators to continue to use individuals' protected health information until they withdrawal their authorization for such use in writing.
Healthcare Delivery and Policy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only